Page 3 - Iontech News Today

The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.

European Commission President Ursula von der Leyen said last week at the Global Gateway Forum in Brussels that she funded a 1.2 billion euro project through which BioNTech and Univercells built modular factories in Rwanda for the production of the vaccine with messenger RNA.

Global Gateway, the European Union's euro300 billion global investment program, appears to be one in which the von der Leyens take the lion's share.

Pfizer and BioNTech announced Thursday it would soon begin a Phase 3 trial for its combined flu and COVID-19 mRNA vaccine following “positive” results from its Phase 1/2 study. Phase 1 and 2 trials are meant to evaluate whether a new drug or treatment is both safe and effective. An official for Pfizer said Thursday…

BioNTech SE (BNTX) shares are adding more than 4 percent on Tuesday morning trade after the company reported positive data for its first-in-human Phase 1/2 trial of Claudin-6, CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors.

Construction site visualization and progress tracking company broadening its scope.

Researchers found a link between covid-19 and Guillain-Barré syndrome, while also finding that mRNA vaccination may lower the risk.

BioNTech gains rights to a MediLink Therapeutics antibody drug conjugate that targets tumors expressing the HER3 protein. The deal comes six months after the German company entered the ADC field by acquiring rights to two therapeutic candidates from DualityBio.

Pfizer, BioNTech and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome's lawsuit accusing the COVID-19 vaccine makers of infringing a patent related to messenger RNA technology. The companies said in a court filing on Wednesday that Promosome would dismiss its case with prejudice, which means it cannot be refiled, and that Promosome had agreed not to bring future claims over the patent against Pfizer and its partner BioNTech.

The awarding of the Nobel Prize to Katalin Karikó and Drew Weissman is justly deserved and has all the more significance in that it takes place under conditions of a vast right-wing anti-science campaign.